Comparison

Etripamil European Partner

Manufacturer MedChem Express
Category
Type Inhibitors
Specific against other
Amount 10mM*1mL
Item no. HY-17611-10mM*1mL
CASRN 1593673-23-4
Available
Product Description
Etripamil (MSP-2017) is a short-acting L-type calcium-channel antagonist, can be used for the research of Paroxysmal Supraventricular Tachycardia (PSVT). Etripamil (MSP-2017) slows atrioventricular nodal conduction and prolongs atrioventricular nodal refractory periods by inhibiting calcium ion influx through the calcium slow channels in the atrioventricular node cells.
StorageTemperature
Pure form -20°C 3 years, 4°C 2 years; In solvent -80°C 6 months, -20°C 1 month
Applications
COVID-19-immunoregulation
Formula
C27H36N2O4
References
[1].Stambler BS, et al. Etripamil Nasal Spray for Rapid Conversion of Supraventricular Tachycardia to Sinus Rhythm. J Am Coll Cardiol. 2018 Jul 31; 72(5):489-497. | [2].Milestone Pharmaceuticals Announces USAN Approval of Generic Name “Etripamil” for its Phase 2 Clinical Development Product for the Treatment of Paroxysmal Supraventricular Tachycardia.
MolecularWeight
452.59
Research Area
Cardiovascular Disease
Solubility
Ethanol : 120 mg/mL (265.14 mM; Need ultrasonic)
Target
Calcium Channel
Isoform
L-type calcium channel
Pathway
Membrane Transporter/Ion Channel; Neuronal Signaling

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

Amount: 10mM*1mL
Available: In stock
available

Delivery expected until 4/13/2023 

Compare

Add to wishlist

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close